Skip to content
HowShorted

CRISPR Therapeutics AG short interest in 2022

In 2022, CRISPR Therapeutics AG's disclosed short interest ran from 11.15% of shares outstanding on 14 Jan 2022 to 13.39% on 30 Dec 2022, a change of +2.24 percentage points. The year's high was 16.02% on 31 Oct 2022 and its low 10.72% on 31 Jan 2022, averaging 13.49% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.65 days on 30 Nov 2022. Full history: CRISPR Therapeutics AG.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CRISPR Therapeutics AG in 2022

2022 in figures

Start of year
11.15% (14 Jan 2022)
End of year
13.39% (30 Dec 2022)
Change
+2.24 pp
High
16.02% (31 Oct 2022)
Low
10.72% (31 Jan 2022)
Average
13.49%
Highest days to cover
14.65 (30 Nov 2022)
SEC filings marked
8

Every report in 2022

CRISPR Therapeutics AG short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202211.15%5.26
31 Jan 202210.72%3.88
15 Feb 202211.33%6.0010-K filed, results (8-K)
28 Feb 202211.89%6.23
15 Mar 202212.18%6.13
31 Mar 202213.04%6.08
14 Apr 202213.47%9.19
29 Apr 202213.16%9.31
13 May 202214.23%6.3010-Q filed, results (8-K)
31 May 202213.21%8.51
15 Jun 202213.73%5.72
30 Jun 202214.62%3.23
15 Jul 202214.88%4.69
29 Jul 202214.16%8.05
15 Aug 202213.74%8.4810-Q filed, results (8-K)
31 Aug 202213.95%10.08
15 Sep 202214.02%9.91
30 Sep 202214.82%9.53
14 Oct 202215.08%11.33
31 Oct 202216.02%12.51
15 Nov 202214.86%9.6910-Q filed, results (8-K)
30 Nov 202214.23%14.65
15 Dec 202211.93%8.88
30 Dec 202213.39%8.42

See also: CRISPR Therapeutics AG's full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.